Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study

被引:14
|
作者
Shorr, Andrew F. [1 ]
Zilberberg, Marya D. [2 ,3 ]
Kan, Jason [4 ]
Hoffman, Justin [4 ]
Micek, Scott T. [4 ]
Kollef, Marin H. [5 ]
机构
[1] Washington Hosp Ctr, Pulm & Crit Care Med Div, Washington, DC 20010 USA
[2] EviMed Res Grp LLC, Goshen, MA USA
[3] Univ Massachusetts, Amherst, MA 01003 USA
[4] Jewish Hosp St Louis, Dept Pharm Barnes, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA
来源
BMJ OPEN | 2013年 / 3卷 / 06期
关键词
COMMUNITY-ACQUIRED PNEUMONIA; RESISTANT PATHOGENS; MACROLIDES; INTERLEUKIN-8; EPIDEMIOLOGY; VALIDATION; OUTCOMES; RISK;
D O I
10.1136/bmjopen-2013-002898
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Streptococcus pneumoniae (SP) represents a major pathogen in pneumonia. The impact of azithromycin on mortality in SP pneumonia remains unclear. Recent safety concerns regarding azithromycin have raised alarm about this agent's role with pneumonia. We sought to clarify the relationship between survival and azithromycin use in SP pneumonia. Design: Retrospective cohort. Setting: Urban academic hospital. Participants: Adults with a diagnosis of SP pneumonia (January-December 2010). The diagnosis of pneumonia required a compatible clinical syndrome and radiographic evidence of an infiltrate. Intervention: None. Primary and secondary outcome measures: Hospital mortality served as the primary endpoint, and we compared patients given azithromycin with those not treated with this. Covariates of interest included demographics, severity of illness, comorbidities and infection-related characteristics (eg, appropriateness of initial treatment, bacteraemia). We employed logistic regression to assess the independent impact of azithromycin on hospital mortality. Results: The cohort included 187 patients (mean age: 67.0 +/- 8.2 years, 50.3% men, 5.9% admitted to the intensive care unit). The most frequently utilised non-macrolide antibiotics included: ceftriaxone (n=111), cefepime (n=31) and moxifloxacin (n=22). Approximately two-thirds of the cohort received azithromycin. Crude mortality was lower in persons given azithromycin (5.6% vs 23.6%, p<0.01). The final survival model included four variables: age, need for mechanical ventilation, initial appropriate therapy and azithromycin use. The adjusted OR for mortality associated with azithromycin equalled 0.26 (95% CI 0.08 to 0.80, p=0.018). Conclusions: SP pneumonia generally remains associated with substantial mortality while azithromycin treatment is associated with significantly higher survival rates. The impact of azithromycin is independent of multiple potential confounders.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Aspiration Pneumonia by Monoclonal Growth of Streptococcus pneumoniae
    Fujita, Jiro
    Tasato, Daisuke
    Arakaki, Wakako
    Uechi, Kohei
    INTERNAL MEDICINE, 2020, 59 (07) : 1011 - 1012
  • [32] Pyogenic Ventriculitis Secondary to Streptococcus Pneumoniae Pneumonia
    Qadri, A. N.
    Rozzi, R.
    Burke, C.
    Jibawi, N.
    Sundaram, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [33] Effect of azithromycin combined with ambroxol in children with Mycoplasma pneumoniae pneumonia
    Ni, Yan
    Fang, Meixin
    Jiang, Juping
    Lou, Qiongqing
    Wu, Licheng
    Liu, Zhiyun
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2023, 15 (01): : 202 - 212
  • [34] Azithromycin prophylaxis during a hospital outbreak of Mycoplasma pneumoniae pneumonia
    Hyde, TB
    Gilbert, M
    Schwartz, SB
    Zell, ER
    Watt, JP
    Thacker, WL
    Talkington, DF
    Besser, RE
    JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (06): : 907 - 912
  • [35] Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis
    Klausner, JD
    Passaro, D
    Rosenberg, J
    Thacker, WL
    Talkington, DF
    Werner, SB
    Vugia, DJ
    JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (01): : 161 - 166
  • [36] Efficacy of treatment and survival rate of foals with pneumonia: Retrospective comparison of rifampin/azithromycin and rifampin/tulathromycin
    Arnold-Lehna, Denise
    Venner, Monica
    Berghaus, Londa J.
    Berghaus, Roy
    Giguere, Steeve
    PFERDEHEILKUNDE, 2019, 35 (05): : 423 - 429
  • [37] A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae
    Md. Oliullah Rafi
    Khattab Al-Khafaji
    Santi M. Mandal
    Nigar Sultana Meghla
    Polash Kumar Biswas
    Md. Shahedur Rahman
    Network Modeling Analysis in Health Informatics and Bioinformatics, 12
  • [38] A subunit vaccine against pneumonia: targeting Streptococcus pneumoniae and Klebsiella pneumoniae
    Rafi, Md. Oliullah
    Al-Khafaji, Khattab
    Mandal, Santi M. M.
    Meghla, Nigar Sultana
    Biswas, Polash Kumar
    Rahman, Md. Shahedur
    NETWORK MODELING AND ANALYSIS IN HEALTH INFORMATICS AND BIOINFORMATICS, 2023, 12 (01):
  • [39] Comparative study of community-acquired pneumonia caused by Streptococcus pneumoniae, Legionella pneumophila or Chlamydia pneumoniae
    Sopena, N
    Pedro-Botet, L
    Sabrià, M
    García-Parés, D
    Reynaga, E
    García-Nuñez, M
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2004, 36 (05) : 330 - 334
  • [40] BACTEREMIC PNEUMONIA BY STREPTOCOCCUS-PNEUMONIAE - A PROSPECTIVE-STUDY OF 31 CASES
    CACHOT, JT
    FLORES, AG
    BROQUETES, J
    DROBNIC, L
    MEDICINA CLINICA, 1987, 89 (04): : 172 - 173